参附注射液对院外心脏骤停后生存与神经功能结局的影响:一项随机对照试验
该随机、评估者盲法对照试验自北京急救中心纳入2013年1月至2016年6月救治的1233例院外心脏骤停患者,比较参附注射液联合肾上腺素标准治疗与单用肾上腺素标准治疗。主要终点入院生存率两组无显著差异,复苏成功、出院生存率和一年生存率亦无显著差异。但参附组出院时神经功能良好结局的OR为2.72(95%CI 1.00-8.53),一年生存者脑功能表现分类(CPC)1-2分的OR为5.08(95%CI 1.07-47.80)。作者认为参附注射液联合肾上腺素较单用肾上腺素对院外心脏骤停后的神经功能结局有有利影响,而入院生存率未见显著改变。
要点
- 院外心脏骤停患者中,参附注射液联合肾上腺素与单用肾上腺素相比,入院生存率无显著差异。
- 参附组出院时神经功能良好结局的OR为2.72(95%CI 1.00-8.53),置信区间上限较高。
- 一年生存者中,参附组CPC 1-2分的OR为5.08(95%CI 1.07-47.80),置信区间很宽。
- 两组复苏成功、出院生存率和一年生存率均无显著差异。
- 作者认为参附注射液联合肾上腺素对院外心脏骤停后神经功能结局有有利影响,但入院生存率未显著改变。
适用人群与场景
- 北京急救中心2013年1月至2016年6月救治的院外心脏骤停患者,共1233例。
处置流程与药物剂量
- 治疗组接受参附注射液联合肾上腺素标准治疗,对照组接受单用肾上腺素标准治疗;原文未报告参附注射液的具体剂量、给药途径和疗程。
研究设计与关键结果
- 随机、评估者盲法对照试验,纳入1233例院外心脏骤停患者,比较参附注射液联合肾上腺素与单用肾上腺素。
- 主要终点入院生存率两组无显著差异;复苏成功、出院生存率和一年生存率亦无显著差异。
- 出院时神经功能良好结局:参附组 vs 对照组 OR 2.72(95%CI 1.00-8.53)。
- 一年生存者CPC 1-2分:参附组 vs 对照组 OR 5.08(95%CI 1.07-47.80)。
证据类型、等级与局限
- 证据类型:随机、评估者盲法对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,参附注射液联合肾上腺素较单用肾上腺素对院外心脏骤停后的神经功能结局有有利影响,而入院生存率未显著改变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: We aimed to assess the effects of Shenfu injection (SFI) in combination with epinephrine during cardiac arrest on survival and neurological outcome after out-of-hospital cardiac arrest (OHCA).
METHODS: In this randomised, assessor-blind controlled trial, Utstein-style data were collected from 1233 OHCA patients treated at the Beijing Emergency Medical Center between January 2013 and June 2016. The patients were randomised into either a treatment group that received a combination of SFI and standard treatment with epinephrine or a control group that received standard treatment with epinephrine alone. The primary outcome was survival to hospital admission. The secondary outcomes were return of spontaneous circulation (ROSC), survival to hospital discharge, favourable neurological outcome at discharge, survival to one year, and favourable neurological outcome at one-year survival.
RESULTS: In both groups, the survival to hospital admission, ROSC, survival to hospital discharge, and one-year survival rate after discharge from the hospital did not differ significantly. However, SFI achieved favourable neurological outcome at discharge in comparison with the standard treatment with an odds ratio (OR) of 2.72 at a 95% confidence interval (CI; 1.00-8.53). Meanwhile, unlike with epinephrine alone, the combination of SFI and epinephrine achieved a better cerebral performance category (CPC) score (1-2) after one-year survival (OR: 5.08, 95% CI: 1.07-47.80).
CONCLUSION: The combination of SFI and epinephrine had favourable neurological outcomes after OHCA compared with those with epinephrine alone, whereas the survival to admission was not significantly altered.
参考来源
- Shao F, Li H, Li D, et al. Effects of Shenfu injection on survival and neurological outcome after out-of-hospital cardiac arrest: A randomised controlled trial. Resuscitation. 2019. PMID: 31770574. doi:10.1016/j.resuscitation.2019.11.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。